Navigation Links
Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
Date:10/29/2010

s issued by Angiotech or to include such information in documents required to be filed with the applicable United States or Canadian securities regulatory authorities or otherwise make such information publicly available.

The projections and other forward looking financial information found herein were not, when made, and are not, historical facts but are forward looking statements about the objectives, strategies, financial conditions, results of operations and businesses of Angiotech and its subsidiaries and are subject to important risks, uncertainties and assumptions.  The forward looking statements and projections set out in this press release are, in the case of Angiotech's Base Medical Products and Proprietary Medical Products businesses, based upon Angiotech's reasonable estimates, assumptions and expectations about these businesses and the markets in which Angiotech operates at the time such information was prepared, or in the case of Angiotech's Royalty business, are derived based upon certain publicly available information, including analyst reports and other sources, regarding expectations for certain products, in particular for sales of paclitaxel-eluting stents by certain of our partners from which we derive or expect to derive royalty revenue pursuant to intellectual property licensing agreements with those partners.  In each case, such projections or forward looking statements are subject to significant business, economic, competitive and other uncertainties and contingencies (including those set out under the heading "Risk Factors" contained in Angiotech's Annual Report on Form 10-K for the year ended December 31, 2009, as updated in Angiotech's most recent Form 10-Q and Management's Discussion and Analysis for the six months ended June 30, 2010), which are beyond Angiotech's or our partners' control.

In addition, forward looking statements reflect numerous assumptions by Angiotech and industry analysts with respect to fu
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
2. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
3. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
4. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
5. Angiotech Pharmaceuticals announces time change of conference call and webcast
6. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
7. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
8. Angiotech announces positive results from Bio-Seal(TM) clinical study
9. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
10. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
11. Angiotech announces date of annual general meeting of shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... A new report by  visiongain ... reach $22.4bn in 2019. That revenue forecast and others ... Prospects 2015-2025 ,  published in March 2015. ... provide forecasts and qualitative analyses of the antithrombotic drugs ... in London, UK . It produces ...
(Date:5/1/2015)... RESEARCH TRIANGLE PARK, N.C. , May 1, 2015 /PRNewswire/ ... Roger Jeffs , Ph.D., President and Co-Chief Executive Officer ... the company,s business at the Deutsche Bank 40 th ... . The presentation will take place on Wednesday, ... be accessed via a live webcast on the United Therapeutics ...
(Date:4/30/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) reported total ... were $4.4 million, compared to $8.0 million during the same ... quarter was $8.9 million, or $0.23 per basic and diluted ... same period in 2014, of $8.7 million, or $0.27 per ... cash, cash equivalents and investments totaled $117.5 million. , ...
(Date:4/30/2015)... The following is an open letter sent April 30, 2015 ... (NYSE: CO ) from Jayhawk Capital. We ... China Cord Blood Corp (" China Cord ") will REJECT ... Golden Meditech Holdings Co Ltd ("Golden Med"). Certainly, a going ... Med and Mr. Kam, the Chairman of both China ...
Breaking Biology Technology:Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5
... the Middle Class Using India,s Private Health Care System, ... be an Increasing Need for Diagnostic Imaging Equipment, ... that growing demand for private health care in India ... a result, the,market will experience rapid growth, reaching a ...
... Ventures, Khosla Ventures, Kleiner Perkins ... and TPG Ventures, Strong Endorsement of Technology Pioneer at Forefront of Developing ... ... development of renewable hydrocarbon biofuels, today,announced that it closed the first tranche of ...
... ,Arpida Ltd (SWX: ARPN) was invited to present ... antimicrobial agents at the 47th annual,Interscience Conference on ... a major scientific conference where thousands of,scientists and ... discuss the,latest developments in the field of infectious ...
Cached Biology Technology:Not Just for the Rich: India's Private Health Care is Booming 2Amyris Biotechnologies Announces $70 Million Series B Round 2Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 2Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 3
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2
... If that office inkjet printer has become just another ... Similar technology may soon be used to develop paper-based ... food poisoning or be used as bioterrorism agents. In ... Chemistry , John Brennan and his research team at McMaster ...
... The destructive cellular pathways activated in Alzheimer,s disease ... researchers from Georgetown University Medical Center (GUMC). They ... successfully target both conditions. In an oral ... on Alzheimer,s Disease, the scientists will show that ...
... June 22 The Federal Bureau of Investigation (FBI) ... a five-year, $47 million contract to continue managing the ... Service (CSS) program. The contract covers the conversion of ... electronic records for the FBI. , , ...
Cached Biology News:Toxin detection as close as an inkjet printer 2Alzheimer's disease drug treats traumatic brain injury, report GUMC researchers 2Federal Bureau of Investigation Awards Lockheed Martin Biometric Card Scanning Service Contract 2
... p- methoxyhydrocinnamamido)-3′-deoxy-N,N-dimethyladenosine, 2HCl White ... Protein synthesis inhibitor. Inhibits translation by ... chains. Induces DNA fragmentation in thymocytes ... Purity: ≥98% by TLC. ...
... Stabilizer is a bovine protein-free alternative ... is an aqueous solution that contains ... buffer (3-(N-Morpholino) propanesulfonic acid), pH 6.0 ... of 0.02% methylisothiazolone and 0.02% bromonitrodioxane ...
... The DNA quantitation kit is used to ... the presence of RNA or protein. With this ... which can be detected with a VersaFluor or ... range of 10 ng per ml to 5 ...
... Reagent A: MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide), ... that is cleaved by living cells to ... process requires active mitochondria, and even freshly ... of MTT. Reagent A is a component ...
Biology Products: